IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Virbac Reports 7.4% H1 Growth, Confirms 2026 Guidance — 3hVirbac reported H1 2026 revenue of €768 million, up 7.4% organically with an 18.8% adjusted EBIT margin and €87.1 million net profit, while net debt rose to about €196 million due to seasonal working capital. Management reaffirmed 2026 targets at the upper end of a 5.5%–7.5% revenue-growth range and around 17% adjusted recurring operating margin, supported by the scaling of its Supercharge platforms and the Thyronorm integration across global markets as part of its 2030 strategy.

Derek Foss Reaffirming the upper end of 2026 guidance suggests the Thyronorm rollout and Supercharge platforms are on track.